• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Key challenges for drugs in clinical development for cholangiocarcinoma.

作者信息

Keenan Bridget P, Kelley R Kate Katie

机构信息

Division of Hematology/Oncology, Department of Medicine, University of California San Francisco and Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.

出版信息

Expert Opin Investig Drugs. 2021 Apr;30(4):285-290. doi: 10.1080/13543784.2021.1880565. Epub 2021 Feb 2.

DOI:10.1080/13543784.2021.1880565
PMID:33530767
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11994244/
Abstract
摘要

相似文献

1
Key challenges for drugs in clinical development for cholangiocarcinoma.胆管癌临床开发中药物面临的关键挑战。
Expert Opin Investig Drugs. 2021 Apr;30(4):285-290. doi: 10.1080/13543784.2021.1880565. Epub 2021 Feb 2.
2
Understanding drug resistance mechanisms in cholangiocarcinoma: assisting the clinical development of investigational drugs.了解胆管癌的耐药机制：助力研究性药物的临床开发。
Expert Opin Investig Drugs. 2021 Jul;30(7):675-679. doi: 10.1080/13543784.2021.1916912. Epub 2021 May 2.
3
The impact of molecular profiling on cholangiocarcinoma clinical trials and experimental drugs.分子图谱对胆管癌临床试验及实验性药物的影响。
Expert Opin Investig Drugs. 2021 Apr;30(4):281-284. doi: 10.1080/13543784.2021.1849139. Epub 2020 Nov 23.
4
Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma.联合生物制剂和化疗治疗胆管癌。
Expert Rev Anticancer Ther. 2011 Apr;11(4):589-600. doi: 10.1586/era.11.17.
5
Cholangiocarcinoma: shedding light on the most promising drugs in clinical development.胆管癌：探索临床开发中最有前途的药物。
Expert Opin Investig Drugs. 2021 Apr;30(4):419-427. doi: 10.1080/13543784.2021.1897103. Epub 2021 Mar 7.
6
Systemic Therapy for Primary Liver Tumors: Cholangiocarcinoma and Hepatocellular Carcinoma.原发性肝脏肿瘤的全身治疗：胆管癌和肝细胞癌
Surg Oncol Clin N Am. 2019 Oct;28(4):695-715. doi: 10.1016/j.soc.2019.06.015.
7
Novel targeted treatment options for advanced cholangiocarcinoma.新型胆管癌靶向治疗选择。
Expert Opin Investig Drugs. 2018 Sep;27(9):709-720. doi: 10.1080/13543784.2018.1512581. Epub 2018 Aug 30.
8
Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials.胆管癌中可成药的分子改变：临床试验中的潜在及当前治疗应用
Expert Opin Investig Drugs. 2021 Sep;30(9):975-983. doi: 10.1080/13543784.2021.1964470. Epub 2021 Aug 22.
9
Highlights of topic "Biochemical and molecular pathological aspects of cholangiocarcinoma".“胆管癌的生化与分子病理学方面”主题要点
J Hepatobiliary Pancreat Sci. 2014 Jun;21(6):359-61. doi: 10.1002/jhbp.91.
10
c-Met targeted therapy of cholangiocarcinoma.胆管癌的c-Met靶向治疗
World J Gastroenterol. 2008 May 21;14(19):2990-4. doi: 10.3748/wjg.14.2990.

引用本文的文献

1
Applications of 3D models in cholangiocarcinoma.3D模型在胆管癌中的应用。
Front Oncol. 2025 Jul 31;15:1598552. doi: 10.3389/fonc.2025.1598552. eCollection 2025.
2
Recent Advances in Immunotherapy for Advanced Biliary Tract Cancer.免疫治疗在晚期胆道癌中的最新进展。
Curr Treat Options Oncol. 2024 Aug;25(8):1089-1111. doi: 10.1007/s11864-024-01243-y. Epub 2024 Jul 27.
3
Epidermal growth factor rs4444903 polymorphism and risk of cholangiocarcinoma. A case control study.表皮生长因子rs4444903多态性与胆管癌风险。一项病例对照研究。
Clin Exp Hepatol. 2023 Jun;9(2):138-145. doi: 10.5114/ceh.2023.128131. Epub 2023 Jun 30.
4
Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer: The Phase 2b NIFTY Randomized Clinical Trial.经治转移性胆道癌患者的脂质体伊立替康联合氟尿嘧啶和亚叶酸治疗：NIFTY 随机 2b 期临床试验。
JAMA Oncol. 2023 May 1;9(5):692-699. doi: 10.1001/jamaoncol.2023.0016.
5
An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma.《肝内胆管癌中生物标志物检测最佳实践的专家、多学科视角》。
Oncologist. 2022 Oct 1;27(10):884-891. doi: 10.1093/oncolo/oyac139.
6
Optimizing the Diagnosis and Biomarker Testing for Patients with Intrahepatic Cholangiocarcinoma: A Multidisciplinary Approach.优化肝内胆管癌患者的诊断和生物标志物检测：一种多学科方法。
Cancers (Basel). 2022 Jan 13;14(2):392. doi: 10.3390/cancers14020392.

本文引用的文献

1
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.帕博利珠单抗治疗的晚期实体瘤患者肿瘤突变负荷与结局的相关性：多队列、开放标签、Ⅱ期 KEYNOTE-158 研究的前瞻性生物标志物分析。
Lancet Oncol. 2020 Oct;21(10):1353-1365. doi: 10.1016/S1470-2045(20)30445-9. Epub 2020 Sep 10.
2
Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update.癌症患者治疗前的乙型肝炎病毒筛查和管理：ASCO 临时临床意见更新。
J Clin Oncol. 2020 Nov 1;38(31):3698-3715. doi: 10.1200/JCO.20.01757. Epub 2020 Jul 27.
3
Cholangiocarcinoma 2020: the next horizon in mechanisms and management.胆管癌 2020：机制和管理的新前沿。
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588. doi: 10.1038/s41575-020-0310-z. Epub 2020 Jun 30.
4
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.ivosidenib 治疗 IDH1 突变、化疗耐药性胆管癌（ClarIDHy）：一项多中心、随机、双盲、安慰剂对照、3 期研究。
Lancet Oncol. 2020 Jun;21(6):796-807. doi: 10.1016/S1470-2045(20)30157-1. Epub 2020 May 13.
5
Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies.派姆单抗治疗晚期胆道癌的疗效和安全性：KEYNOTE-158 和 KEYNOTE-028 研究结果。
Int J Cancer. 2020 Oct 15;147(8):2190-2198. doi: 10.1002/ijc.33013. Epub 2020 May 2.
6
A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.纳武利尤单抗治疗晚期难治性胆道癌患者的 2 期多中心研究。
JAMA Oncol. 2020 Jun 1;6(6):888-894. doi: 10.1001/jamaoncol.2020.0930.
7
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.培米替尼治疗既往治疗过的局部晚期或转移性胆管癌：一项多中心、开放标签、2 期研究。
Lancet Oncol. 2020 May;21(5):671-684. doi: 10.1016/S1470-2045(20)30109-1. Epub 2020 Mar 20.
8
Pan-Cancer Efficacy of Vemurafenib in -Mutant Non-Melanoma Cancers.泛癌种中维莫非尼对 - 突变型非黑色素瘤肿瘤的疗效。
Cancer Discov. 2020 May;10(5):657-663. doi: 10.1158/2159-8290.CD-19-1265. Epub 2020 Feb 6.
9
Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma.鉴定四种免疫亚型，其特点是肿瘤微环境的组成和功能明显不同，在肝内胆管癌中。
Hepatology. 2020 Sep;72(3):965-981. doi: 10.1002/hep.31092. Epub 2020 Aug 16.
10
Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes.二线化疗在晚期胆道癌中的应用：一项回顾性、多中心结局分析。
Cancer. 2019 Dec 15;125(24):4426-4434. doi: 10.1002/cncr.32463. Epub 2019 Aug 27.